Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/06/2008WO2008026768A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
03/06/2008WO2008026765A2 Lyophilized preparation
03/06/2008WO2008026756A1 Ophthalmic percutaneous absorption type preparation
03/06/2008WO2008026748A1 Antitumor agent for undifferentiated gastric cancer
03/06/2008WO2008026729A1 Therapeutic agent for pigmented villonodular synovitis or giant cell tumor of tendon sheath or bone
03/06/2008WO2008026704A1 Isoquinoline derivative
03/06/2008WO2008026702A1 Pharmaceutical composition containing statin-encapsulated nanoparticle
03/06/2008WO2008026687A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor comprising the derivative
03/06/2008WO2008026668A1 Medicinal composition containing insulin resistance improving agent
03/06/2008WO2008026644A1 Hydrophilic matrix having poorly water-soluble compound sealed therein, and method for producing the same
03/06/2008WO2008026577A1 Method for producing phenoxypyridine derivative
03/06/2008WO2008026564A1 Urea derivative
03/06/2008WO2008026563A1 Hydrazine amide derivative
03/06/2008WO2008026556A1 Freeze-dried preparation of 1-methylcarbapenem
03/06/2008WO2008026507A1 Skin whitening agent
03/06/2008WO2008026381A1 Nail patch
03/06/2008WO2008026310A1 Protective agent for oral mucosa containing trehalose
03/06/2008WO2008026300A1 Neem seed-derived therapeutic agent for malignant tumor
03/06/2008WO2008026298A1 Remedy for kidney disease
03/06/2008WO2008026234A2 Method to identify and treat subjects resistant to acetyl salicylic acid
03/06/2008WO2008026220A1 A process for purification of 7-(4-bromobutoxy)-3,4 dihydrocarbostyril, an intermediate for manufacture of aripirazole
03/06/2008WO2008026172A1 Spiro antibiotic derivatives
03/06/2008WO2008026156A2 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008WO2008026149A1 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
03/06/2008WO2008026125A2 Anti cancer use of caffeic acid and derivatives
03/06/2008WO2008026046A1 Morpholine d3 dopamine antagonists
03/06/2008WO2008026018A1 New method for the treatment of inflammatory diseases
03/06/2008WO2008026014A1 Management of non septic patients suffering from partial thickness burns during the first 48 postburn hours by administration of activated protein c
03/06/2008WO2008026012A1 Novel compositions and methods
03/06/2008WO2008025947A1 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
03/06/2008WO2008025870A1 Compositions useful especially for treatment or prevention of metabolic syndrome
03/06/2008WO2008025847A2 Use of c7 sugars in prevention and treatment of mycoses
03/06/2008WO2008025822A1 Diazolodiazine derivatives as kinase inhibitors
03/06/2008WO2008025821A1 Triazole derivatives as kinase inhibitors
03/06/2008WO2008025820A1 Aminopyridine derivates as kinase inhibitors
03/06/2008WO2008025819A2 Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
03/06/2008WO2008025816A1 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
03/06/2008WO2008025800A1 Pyrimidine compounds for treating gpr119 related disorders
03/06/2008WO2008025799A1 Pyridazine compounds for treating gpr119 related disorders
03/06/2008WO2008025798A1 Pyridine compounds for treating gpr119 related disorders
03/06/2008WO2008025791A1 Buprenophine-wafer for drug substitution therapy
03/06/2008WO2008025790A2 Use of opioid formulations in needle-less drug delivery devices
03/06/2008WO2008025787A2 Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
03/06/2008WO2008025781A1 Bifeprunox doses for treating schizophrenia
03/06/2008WO2008025780A1 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
03/06/2008WO2008025777A1 Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/06/2008WO2008025773A1 Pharmaceutical compositions comprising cefquinome
03/06/2008WO2008025736A1 Substituted benzimidazolone derivatives, medicaments comprising them and their use
03/06/2008WO2008025735A1 Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands
03/06/2008WO2008025694A1 Inhibitors for glyt-1
03/06/2008WO2008025560A1 Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
03/06/2008WO2008025556A1 Sulphoximides as protein kinase inhibitors
03/06/2008WO2008025543A1 Pharmaceutical compositions for the treatment of fungal infections
03/06/2008WO2008025541A1 Polymorph of (r) -3- (2-hydroxy-2, 2-diphenyl-acetoxy) -1- (isoxazol-s-ylcarbamoyl-methyl) -1-azoni a-bicyclo- [2.2.2] octane bromide
03/06/2008WO2008025540A1 Heterocyclic fxr binding compounds
03/06/2008WO2008025539A1 Heterocyclic fxr binding compounds
03/06/2008WO2008025534A1 Preparation and purification of mupirocin calcium
03/06/2008WO2008025532A1 Controlled release solid oral dosage formulations comprising nisoldipine
03/06/2008WO2008025526A1 Indole derivatives, their manufacture and use as pharmaceutical agents
03/06/2008WO2008025512A1 Pyrrolo isoquinolines as kinase inhibitors
03/06/2008WO2008025511A1 Improved preparation for reducing and/or preventing body fat and respective uses, in particular together with a dressing material
03/06/2008WO2008025509A1 Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
03/06/2008WO2008025450A1 Methods of lowering glucose levels
03/06/2008WO2008025449A1 Treating mycobacterial infections with cyclipostins
03/06/2008WO2008025361A1 3-(1h-indol-3-yl) indan-1-ylamine derivatives for the treatment of depression and anxiety
03/06/2008WO2008025228A1 The antibiotics composition comprising beta-lactam antibiotics and buffers
03/06/2008WO2008025227A1 The antibiotics composition comprising aminoglycoside antibiotics
03/06/2008WO2008025226A1 The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents
03/06/2008WO2008025170A1 Selective glycosidase inhibitors and uses thereof
03/06/2008WO2008025160A1 Oxepane nucleosides and oligonucleotides, uses thereof and methods of making the same
03/06/2008WO2008025152A1 Antibacterial agents
03/06/2008WO2008025148A1 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
03/06/2008WO2008025116A1 Composition and method for enhancing or promoting the activity of insulin, enhancing skeletal muscle growth, reducing skeletal muscle loss, and increasing the energy supply to skeletal muscle
03/06/2008WO2008025115A1 Method of increasing intracellular concentrations of phosphate and increasing the force of muscular contractions
03/06/2008WO2008025114A1 Increasing atp availability by inhibition of creatine kinase (ck) leakage resulting from high-intensity exercise
03/06/2008WO2008025111A2 Biodegradable device for intraocular drug delivery
03/06/2008WO2008025073A1 Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
03/06/2008WO2008014361A3 Cyclic derivatives as modulators of chemokine receptor activity
03/06/2008WO2008011177A3 Medicinal delivery system and related methods
03/06/2008WO2008011176A9 Myosin light chain kinase inhibitor compounds, compositions and related methods of use
03/06/2008WO2008011174A3 Jak inhibitors for treatment of myeloproliferative disorders
03/06/2008WO2008011110A3 Di-amino-substituted heterocyclic compounds and methods of use
03/06/2008WO2008010984A9 Acridine activation of p53 and uses thereof
03/06/2008WO2008008637A3 Antioxidant combinations for use in ruminant feed rations having a fat source
03/06/2008WO2008008549A3 Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia
03/06/2008WO2008008513A3 Combination treatments
03/06/2008WO2008008432A3 Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
03/06/2008WO2008008375A3 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation
03/06/2008WO2008008327A3 Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
03/06/2008WO2008007152A3 Preparation of pharmaceutical formulations
03/06/2008WO2008007151A3 Processes for preparing pharmaceutical compositions
03/06/2008WO2008007122A3 Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
03/06/2008WO2008006884A3 Mtki quinazoline derivatives
03/06/2008WO2008006795A3 Indole compounds
03/06/2008WO2008006547A3 Pyrrolopyrimidines for pharmaceutical compositions
03/06/2008WO2008005964A3 Phosphonate and phosphinate compounds as glucokinase activators
03/06/2008WO2008005956A3 Pyrrolotriazine kinase inhibitors
03/06/2008WO2008005534A3 Orally dissolving formulations of memantine
03/06/2008WO2008004191A3 Process for the preparation of enantiomerically pure salts of n-methyl-3- ( 1-naphthaleneoxy) -3- (2-thienyl) propanamine
03/06/2008WO2008003958A3 Fused pyrimido compounds
1 ... 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 3361 3362 3363 3364 3365 3366 3367 3368 3369 ... 7860